The mechanism underlying transient weakness in myotonia congenita
preprint
OA: closed
AI-generated summary
Transient weakness in Becker disease results from plateau potentials caused by persistent Na+ current and Ca2+ channel activity, which ranolazine administration can prevent.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In addition to the hallmark muscle stiffness, patients with recessive myotonia congenita (Becker disease) experience debilitating bouts of transient weakness that remain poorly understood despite years of study. We made intracellular recordings from muscle of both genetic and pharmacologic mouse models of Becker disease to identify the mechanism underlying transient weakness. Our recordings reveal transient depolarizations (plateau potentials) of the membrane potential to −25 to −35 mV in the genetic and pharmacologic models of Becker disease. Both Na + and Ca 2+ currents contribute to plateau potentials. Na + persistent inward current (NaPIC) through Naγ1.4 channels is the key trigger of plateau potentials and current through Ca v 1.1 Ca 2+ channels contributes to the duration of the plateau. Inhibiting NaPIC with ranolazine prevents the development of plateau potentials and eliminates transient weakness in vivo. These data suggest that targeting NaPIC may be an effective treatment to prevent transient weakness in myotonia congenita. Impact Statement Transient weakness in myotonia congenita is caused by depolarization secondary to activation of persistent Na + current in skeletal muscle.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00